Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediciNova initiates cystitis trial
Cystitis is a chronic, inflammatory disorder of the urinary bladder characterized by variable degrees of urinary urgency, frequency and bladder pain. MN-001 is an orally administered drug with
Cystitis is a chronic, inflammatory disorder of the urinary bladder characterized by variable degrees of urinary urgency, frequency and bladder pain. MN-001 is an orally administered drug with
The company, which recently entered into an agreement to combine with the San Diego-based firm Epimmune, produces vaccines designed to prevent tumor relapse. The therapies come from the
The study which gathered data between May 2002 and November 2004 confirms the safety profile of bosentan, (marketed as Tracleer), as seen in previous phase III clinical trials.
The researchers compared the safety profiles of the three most commonly used statins, atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol), versus the more recently introduced statin, rosuvastatin (Crestor).
Approved by the FDA in December 2004, Razadyne ER contains galantamine hydrobromide – first approved by the FDA in February 2001 as the twice-daily medication Reminyl. In April
In the study, alagebrium was shown to increase arterial elasticity through the breaking of advanced glycation end-product (AGE) crosslinks and improve endothelial function. As central arterial stiffening and
Scolr Pharma intends to file a new drug application (NDA) known as a 505(b)(2) application, which can be used for products for which substantial evidence of safety and
Insmed and Avecia had made motions for summary judgment, attacking the validity of the Tercica/Genentech patent for SomatoKine. The Court ruled in Tercica’s and Genentech’s favor in denying
After announcing several product recalls earlier this year due to various improper laboratory practices and noncompliance with standard operating procedures, Able notified the FDA and began conducting an
This contract, the first from a major US pharmaceutical company for MultiCell, allows Bristol-Myers Squibb to grow and use MultiCell’s immortalized Fa2N-4 hepatocytes for internal testing purposes. MultiCell’s